Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer

Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer

Background Immunotherapy represented by programmed death protein-1 (PD-1) inhibitors has gradually become the standard treatment of advanced non-small cell lung cancer (NSCLC) in recent years, changing the treatment landscape of advanced NSCLC. However, most PD-1-related studies excluded patients wi...

Full description

Bibliographic Details
Main Author: SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2023-01-01
Series:Zhongguo quanke yixue
Subjects:
aged|carcinoma, non-small-cell lung|immune checkpoint inhibitors|programmed cell death 1 receptor blockades|drug therapy|treatment outcome|safety
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/zx20220567.pdf

Internet

https://www.chinagp.net/fileup/1007-9572/PDF/zx20220567.pdf

Similar Items